Glenbrook Capital Management, which owns roughly ten percent of SenesTech, Inc. (NASDAQ: SNES), has modestly raised its equity stake in the pest-control technology company, according to a Form 4 filed with regulators.
The filing shows Glenbrook purchased a total of 8,569 shares of SenesTech common stock across two transactions totaling $15,479. On February 4, 2026, the firm acquired 5,685 shares at $1.8247 per share. On February 5, 2026, Glenbrook added 2,884 shares at $1.7705 per share. After these trades, Glenbrook Capital Management holds 602,354 shares of SenesTech.
Those moves come amid positive operating updates from SenesTech. The company reported a 43% increase in revenue for the third quarter of 2025, with total revenue reaching $690,000. Management attributed that rise primarily to meaningful sales of its rodent birth control product.
Regulatory progress accompanied the revenue gain. SenesTech's Evolve fertility control solution for rodents received approval for use in New Zealand from the Ministry for Primary Industries. Following that authorization, the company shipped an initial order to its distribution partner, Evicom, marking the first commercial entry of Evolve into the New Zealand market.
On the corporate leadership front, SenesTech announced that President and CEO Joel Fruendt plans to retire. Fruendt will remain in his position until a successor has been named or until June 30, 2026, whichever comes first. The company noted that during Fruendt's tenure he oversaw the rollout of Evolve across multiple channels.
Taken together, the insider purchasing activity, quarterly revenue growth, regulatory approval in New Zealand, and the planned CEO transition represent a cluster of developments that could shape near-term company execution. The Glenbrook purchases were small in dollar terms but occurred while SenesTech reported improving top-line results and expanded its geographic reach for Evolve.
Details on future sales trends, distribution progress beyond the initial New Zealand order, and the timeline for appointing a new CEO were not disclosed in the filings and company statements referenced above.
Summary of the factual items reported:
- Glenbrook Capital Management bought 8,569 shares of SenesTech common stock in two transactions on February 4 and February 5, 2026, totaling $15,479.
- After the purchases, Glenbrook owns 602,354 shares of SenesTech.
- SenesTech reported Q3 2025 revenue of $690,000, a 43% increase attributed mainly to rodent birth control product sales.
- The Evolve product received New Zealand approval from the Ministry for Primary Industries and an initial order was sent to distributor Evicom.
- President and CEO Joel Fruendt announced plans to retire and will remain in his role until a successor is named or until June 30, 2026.